nanocovax vietnamese vaccine candidate developed nanogen pharmaceutical biotechnology subunit vaccine recombinant spike protein aluminum vaccine requires two doses second one administered days first given intramuscular injection vietnamese health ministry assessed nanocovax vaccine produced nanogen promising successfully produced laboratory scale provoked immunogenicity animal testing preclinical studies nanocovax conducted hamsters nonhuman primates including challenge test exposing hamsters december nanogen commenced human trials nanocovax clinical trial phase openlabel doseescalation recruited healthy vietnamese adult volunteers evaluate safety tolerability initial assessment immunogenicity vaccine intramuscularly participants firststage trials nanocovax showed vaccine safe vaccinated volunteers antibodies alpha february pharmaceutical company began second phase trials two places hanoi southern province long clinical trial phase randomization doubleblind multicenter placebocontrolled enrolled healthy volunteers evaluate safety immunogenicity determined optimal dose vaccine intramuscularly participants volunteers receiving dose vaccine receiving march april volunteers receiving first jabs phase ii february march given second shots nanocovax volunteers experienced side effects around injection site yet require medical results trial issued april show homegrown vaccine according trial results people injected dose got highest index days second shot days since first doses research team submitted report research ethics committee ministry health proposed plan third phase human trials dose strength mcg selected phase evaluate vaccine efficacy local adverse effects including pain reported subjects first second doses respectively systemic effects including fatigue headache found participants injection respectively fever rare reported participants doses saes rare however severe back pain reported three patients whereas one patient exhibited serious sepsis another patient experienced severe sore throat milder adverse effects cough sore throat seen less subjects overall adverse events observed within two days often resolved seven days obvious relationship observed dose escalation adverse events rate adverse events vaccinated placebo groups respectively laboratory aberrations hyperglycemia leukocytosis also reported however neither phase paused vaccinations adverse events events angina following stent graft sepsis abscesses personal injury anaphylaxis related vaccination scientists geometric mean concentration gmc antis igg bauml reported injection antis igg level groups lower limit detection bauml antis igg vaccines groups increased remarkably injection day day antis igg levels group nanocovax mcg mcg mcg bauml bauml bauml respectively day respective antis igg increased sharply bauml respectively day respective antis igg levels dropped bauml still higher igg level convalescent group bauml antis igg levels placebo group days bauml respectively geometric mean fold rise gmfr antis igg defined fold increase gmc given timepoint compared baseline gmc value group day gmfr groups nanocovax mcg mcg mcg day respectively day gmfr respective groups day gmfr vaccinated groups decreased meanwhile gmfr placebo group days respectively seroconversion rate defined gmfr based gmfr antis igg seroconversion rates groups nanocovax mcg mcg mcg day day seroconversion rates respective groups day seroconversion rates still high vaccine groups surrogate virus neutralization test svnt results reported mean inhibition rate day vaccination inhibition rates groups cutoff value day mean inhibition groups nanocovax mcg mcg mcg placebo respectively day respective mean inhibition rates day respective svnt meanwhile mean inhibition rate convalescent samples neutralizing antibody levels evaluated plaque reduction neutralization test inhibitory dilution greater expressed geometric mean titers gmt serum samples groups nanocovax mcg mcg mcg placebo randomly selected original wuhan strain uk variant day gmt groups nanocovax mcg mcg mcg respectively day respective gmt approximately times higher gmt convalescent samples meanwhile gmt group placebo days half limit detection lod among serum samples day tested wuhan strain subset randomly selected evaluate neutralizing titer alpha variant gmt group nanocovax mcg mcg mcg alpha variant approximately decrease compared original strain type helper cell response randomly selected participants vaccine group placebo group undetectable likely due nature aluminum adjuvant well established response phase iii study adaptive multicenter randomized doubleblind placebo control study evaluate safety immunogenicity efficacy nanocovax vaccine volunteer subjects years age phase iii human trials nanocovax started june carried people ha noi northern hung yen province mekong delta provinces tien giang long volunteers administered dose stage person receive two jabs set get second shots days first september national ethics committee biomedical research ministry health moh reviewed approved clinical trial results phase iii nanocovax according president national ethics committee biomedical research professor truong viet dung nanocovax vaccine safe produces immune safety findings phase iii study time data cutoff august consistent safety findings nanocovax phase ii studies continue provide evidence supports safety profile nanocovax mcg comparing safety nanocovax dose groups placebo injection group results recorded study showed nanocovax vaccine safe significant difference safety nanocovax injection group placebo group data cutoff date august solicited local adverse events days postinjection nanocovax mcg placebo groups similar incidence pain injection site vaccine placebo groups respectively pain sensitivity swelling injection site redness injection site pruritus injection site solicited local adverse events dose numerically lower dose similar nanocovax placebo groups common adverse event pain injection site occurrence vaccine placebo groups respectively several systemic adverse events also reported showing common systemic adverse events within days injection vaccine placebo groups fatigue headache myalgia joint pain nauseavomiting diarrhea fever solicited systemic adverse events injection reversible without sequelae solicited systemic adverse events days dose similar dose balance vaccine placebo groups common solicited adverse events fatigue myalgia vaccine placebo groups respectively others mild quickly recovered incident unsolicited adverse events vaccine group placebo group including hypotension vestibular disorders knee pain hand pain hyperthyroidism upper respiratory tract inflammation almost unsolicited adverse events related investigational products majority unsolicited nonsae adverse events vaccine place groups mild moderate serious adverse events saes including cases study groups vaccine placebo trial saes assessed unrelated study product four saes assessed possibly related dsmb investigator assessments including grade anaphylactic reaction grade allergic reactions grade hypertension exacerbation chronic obstructive pulmonary disease copd participants recovered completely gmc antis igg binding antibody unit bauml shown injection antis igg level vaccine placebo groups bauml respectively day antis igg concentration vaccine group reached bauml placebo group remained unchanged bauml addition igg response negatively correlated age gmc antis igg groups day bauml respectively correlation coefficient r day gmfr vaccine group meanwhile gmfr placebo group group age highest gmfr followed seroconversion rate defined gmfr day seroconversion rate vaccine group neutralizing antibody qualitatively quantitatively evaluated svnt respectively svnt results reported percentage participants group positive assay day participants vaccine placebo groups positive svnt day vaccine group positive test positive placebo group neutralizing antibody assessed expressed gmt number serum samples vaccine placebo groups day randomly selected assess neutralizing antibody titer original wuhan strain alpha variant delta variant gmt neutralizing antibody wuhan alpha delta respectively meanwhile gmt neutralizing antibody placebo group half lower limit detection found neutralizing antibody level induced nanocovax exceeded convalescent samples type type helper cell response randomly selected participants vaccine group placebo group evaluated ics ifng signal signal dominant ifng signal day suggesting polarization induction nanocovax observation consistent nature aluminum adjuvant well established response induction data cutoff date august vaccine efficacy yet concluded due insufficiency confirmed positive case however accumulated evidences correlated neutralizing antibody level immunity cromer et provided model predict vaccine efficacy comparing neutralizing antibody titers vaccines convalescent samples accordingly neutralizing antibody titer nanocovax injection group times higher recovered group thereby estimating protective effect original wuhan infection delta addition antis igg antibody months vaccination nanocovax vaccine still higher antibody content convalescent comparing immunogenicity results nanocovax convalescent patients evaluated pasteur institute ho chi minh city well immunological results licensed vaccines shown nanocovax vaccine effective preventing national ethics committee biomedical research concluded nanocovax vaccine estimated protective efficacy based immunogenicity data research ensured scientific validity qualified transfer dossier advisory council accordingly dossiers data presenting information search madeinvietnam vaccine submitted mohs advisory council registration circulation drugs medicinal ingredients emergency use vaccine cost vnd around per nanogen currently possesses ability produce million doses year company expecting increase capacity million doses year meet domestic nanocovax vaccine may ready deliver general public second half efficacy government goes ahead emergency decision may rolled may nanogen official told nikkei asia february march deputy minister science technology phạm công tạc deputy prime minister vũ đức đam received second dose nanocovax june general director nanogen said interview company applied emergency authorization nanocovax vietnam week httpsenwikipediaorgwikinanocovax